BioSpace News Archive

Trevena, Inc. today announced results from its double blinded, crossover study evaluating OLINVYK® (oliceridine) injection for the management of acute pain, in elderly/overweight.

XORTX Therapeutics Inc., a pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce receipt of Small and Medium Enterprise status for the European Union.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2022 financial results on Tuesday, May 3, 2022, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 26, 2022 at 8:30 a.m. ET.

Harrow Health, Inc. today announced that it will release its financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022, after the market close.

Clover Biopharmaceuticals, Ltd. today announced additional data from SPECTRA, a global pivotal Phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19.

Genenta Science announced it will hold a webinar entitled “Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors” on Thursday, April 28 , 2022 at 8:00 AM EDT / 2:00 PM CET.

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2022.

Certara, Inc. today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022.

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2022 financial results on Wednesday, May 4, 2022, before the open of the US financial markets.